{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:25:57Z","timestamp":1767925557526,"version":"3.49.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>LRRK2<\/jats:italic> variants have been associated with immune dysregulation as well as immune-related disorders such as IBD. A possible relationship between multiple sclerosis (MS) and <jats:italic>LRRK2<\/jats:italic> PD has also been suggested. Further, neuropathologic studies of homozygous <jats:italic>LRRK2<\/jats:italic> G2019S carriers with Parkinson\u2019s disease (PD) are rare, and there are no systematic reports of clinical features in those cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated the co-occurrence of PD and MS in our research cohort and report on two cases of MS in <jats:italic>LRRK2<\/jats:italic> PD as well as neuropathological findings for one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MS preceded PD in 1.4% (2\/138) of participants with <jats:italic>LRRK2<\/jats:italic> G2019S variants, and in none (0\/638) with idiopathic PD (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). One case with MS and PD was a <jats:italic>LRRK2<\/jats:italic> G2019S homozygous carrier, and neuropathology showed evidence of substantia nigra pars compacta degeneration and pallor without Lewy deposition, as well as multiple white matter lesions consistent with MS-related demyelination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The increased prevalence of MS in <jats:italic>LRRK2<\/jats:italic> PD further supports an important role for immune function for <jats:italic>LRRK2<\/jats:italic> PD. This co-occurrence, while rare, suggests that MS may be an expression of the <jats:italic>LRRK2<\/jats:italic> G2019S variant that includes both MS and PD, with MS predating features diagnostic of PD. The neuropathology suggests that the MS-related effects occurred independent of synuclein deposition. Importantly, and in addition, the neuropathological results not only support the MS diagnosis, but provide further evidence that Lewy body pathology may be absent even in homozygote <jats:italic>LRRK2<\/jats:italic> carriers.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1450654","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:22:15Z","timestamp":1723130535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Multiple sclerosis in LRRK2 G2019S Parkinson\u2019s disease and isolated nigral degeneration in a homozygous variant carrier"],"prefix":"10.3389","volume":"15","author":[{"given":"Adina","family":"Wise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto A.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Leaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan B.","family":"Bressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Crary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Saunders-Pullman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-017-0010-8","article-title":"LRRK2 levels in immune cells are increased in Parkinson's disease","volume":"3","author":"Cook","year":"2017","journal-title":"NPJ Parkinson's Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"634666","DOI":"10.3389\/fnins.2021.634666","article-title":"Inflammatory diseases among Norwegian LRRK2 mutation carriers. A 15-years follow-up of a cohort","volume":"15","author":"Aasly","year":"2021","journal-title":"Front Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/archneur.63.9.1250","article-title":"Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations","volume":"63","author":"Ishihara","year":"2006","journal-title":"Arch Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40478-019-0836-x","article-title":"Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"ref5","first-page":"160","article-title":"Genetic risk variants in New Yorkers of Puerto Rican and Dominican Republic heritage with Parkinson\u2019s disease","volume":"9","author":"Miltenberger-Miltenyi","year":"2023"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.23644","article-title":"Substantia nigra hyperechogenicity with LRRK2 G2019S mutations","volume":"26","author":"Br\u00fcggemann","year":"2011","journal-title":"Mov Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27443","article-title":"Increased substantia Nigra echogenicity in LRRK2 family members without mutations","volume":"33","author":"Pullman","year":"2018","journal-title":"Mov Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/mds.29589","article-title":"An autopsy series of seven cases of VPS13A disease (chorea-Acanthocytosis)","volume":"38","author":"Ditzel","year":"2023","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e814","DOI":"10.1212\/WNL.0000000000200737","article-title":"Association of Olfactory Performance with Motor Decline and age at onset in people with Parkinson disease and the LRRK2 G2019S variant","volume":"99","author":"Saunders-Pullman","year":"2022","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"909303","DOI":"10.3389\/fnagi.2022.909303","article-title":"The double-faceted role of leucine-rich repeat kinase 2 in the Immunopathogenesis of Parkinson's disease","volume":"14","author":"Zhang","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-022-00297-9","article-title":"Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages","volume":"8","author":"Ahmadi Rastegar","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1093\/hmg\/ddv157","article-title":"The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins","volume":"24","author":"Moehle","year":"2015","journal-title":"Hum Mol Genet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3233\/JPD-230021","article-title":"Immunological features of LRRK2 function and its role in the gut-brain Axis governing Parkinson\u2019s disease","volume":"13","author":"Peter","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"eaai7795","DOI":"10.1126\/scitranslmed.aai7795","article-title":"Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease","volume":"10","author":"Hui","year":"2018","journal-title":"Sci Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"105806","DOI":"10.1016\/j.nbd.2022.105806","article-title":"The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases","volume":"172","author":"Tsafaras","year":"2022","journal-title":"Neurobiol Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1600-0404.2004.00244.x","article-title":"Multiple sclerosis in Nord-Tr\u00f8ndelag County, Norway: a prevalence and incidence study","volume":"109","author":"Dahl","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","article-title":"Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease","volume":"72","author":"Kalia","year":"2015","journal-title":"JAMA Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5334\/tohm.671","article-title":"Movement disorders in multiple sclerosis: an update","volume":"12","author":"Ghosh","year":"2022","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10048-019-00588-z","article-title":"Frequency of the LRRK2 G2019S mutation in south African patients with Parkinson's disease","volume":"20","author":"du Toit","year":"2019","journal-title":"Neurogenetics"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mds.21180","article-title":"Screening for LRRK2 G2019S and clinical comparison of Tunisian and north American Caucasian Parkinson's disease families","volume":"22","author":"Ishihara","year":"2007","journal-title":"Mov Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(05)17828-3","article-title":"Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease","volume":"365","author":"Nichols","year":"2005","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc055540","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in north African Arabs","volume":"354","author":"Lesage","year":"2006","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson's progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40478-018-0617-y","article-title":"Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations","volume":"6","author":"Takanashi","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2014.1973","article-title":"Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis","volume":"72","author":"Agalliu","year":"2015","journal-title":"JAMA Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1450654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:22:18Z","timestamp":1723130538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1450654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":25,"alternative-id":["10.3389\/fneur.2024.1450654"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1450654","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"article-number":"1450654"}}